![]() |
|
|
Vol. 289, Issue 3, 1391-1397, June 1999
Institut de Recherche Jouveinal/Parke Davis, Fresnes Cedex, France
(F.J.R., S.L., J.H., G.B.); Centre de Recherches Biologiques, Chemin de
Montifault, Baugy, France (A.M., P.C., S.R.); and Laboratoire de
Neurobiologie, Unité Propre de Recherche, Centre National
de la Recherche Scientifique, Marseille Cedex, France (N.A., M.G.)
Trimebutine [2-dimethylamino-2-phenylbutyl-3,4,5-trimethoxybenzoate
hydrogen maleate (TMB)] has been demonstrated to be active for
relieving abdominal pain in humans. To better understand its mechanism
of action, we have tested TMB; nor-TMB, its main metabolite in humans;
and their respective stereoisomers for their affinity toward sodium
channels labeled by [3H]batrachotoxin, their effect on
sodium, potassium, and calcium currents in rat dorsal root ganglia
neurons, and their effect on veratridine-induced glutamate release from
rat spinal cord slices. TMB has also been tested in an animal model of
local anesthesia. TMB (Ki = 2.66 ± 0.15 µM) and nor-TMB (Ki = 0.73 ± 0.02 µM) displaced [3H]batrachotoxin from its binding
site with affinities similar to that of bupivacaine
(Ki = 7.1 ± 0.9 µM). nor-TMB was
found to block veratridine-induced glutamate release with an
IC50 value of 8.5 µM, which is very similar to that of
bupivacaine (IC50 = 8.2 µM); the effect of TMB was
limited to 50% inhibition at 100 µM. TMB and nor-TMB blocked sodium
currents in sensory neurons from rat dorsal root ganglia
(IC50 = 0.83 ± 0.09 and 1.23 ± 0.19 µM,
respectively), whereas no effect was observed on calcium currents at
the same concentrations. A limited effect was observed on potassium currents (IC50 = 23 ± 6 at 10 µM) for TMB. In vivo,
when tested in the rabbit corneal reflex, TMB displayed a local
anesthetic activity 17-fold more potent than that of lidocaine.
This article has been cited by other articles:
![]() |
J Fioramonti and L Bueno Centrally acting agents and visceral sensitivity Gut, July 1, 2002; 51(90001): i91 - 95. [Abstract] [Full Text] |
||||
![]() |
L. Bueno, J. Fioramonti, and R. Garcia-Villar Pathobiology of Visceral Pain: Molecular Mechanisms and Therapeutic Implications: III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain Am J Physiol Gastrointest Liver Physiol, May 1, 2000; 278(5): G670 - G676. [Abstract] [Full Text] [PDF] |
||||